Health · Medical Research · 11 hrs ago
GLP-1 drugs linked to heart improvements in patients with obesity
Mayo Clinic researchers found heart improvements linked to GLP-1 drugs in patients with obesity and heart failure.
The main study included people whose heart’s left ventricle was weak and did not pump blood effectively.
After one year, the 146 patients taking semaglutide or tirzepatide had greater improvements in heart size, structure and function than 237 similar patients who were not taking the drugs.
The findings do not show that the drugs alone caused the changes, though many improvements remained significant after researchers accounted for weight loss.
A separate study found benefits from semaglutide in people with obesity and a different type of heart failure, including heart failure remission in more than half of treated patients.
Researchers also reported exploratory results suggesting some improvements continued into a second year, but said these could guide future studies.
Lilly said Zepbound may reduce later health care use, but its analysis did not account for what patients paid for the drug, which can cost more than $1,000 a month without insurance.
A study found that patients with obesity and heart failure who took GLP-1 drugs had greater improvements in heart structure and function after one year than a matched group not taking the drugs.
All participants had heart failure with reduced ejection fraction, meaning their heart’s left ventricle was weak at pumping blood.
The GLP-1 group included 146 patients taking semaglutide or tirzepatide, compared with 237 patients in the control group.
Exploratory two-year analyses showed continued improvements in left ventricular ejection fraction and heart size.
Many improvements remained significant after researchers accounted for weight changes, suggesting effects beyond weight loss.
- Who
- Mayo Clinic researchers studied patients with obesity and heart failure with reduced ejection fraction.
- What
- GLP-1 medication use was associated with greater improvements in heart size, structure and function.
- When
- After one year of treatment; the article was published on November 21, 2026.
- Where
- The study was presented at an obesity meeting. The meeting’s location is not stated.
- Why
- The researchers analyzed changes in heart measures among patients taking GLP-1 drugs; a specific study aim is not stated.
This story does not have two clearly opposing sides.
Patients taking GLP-1 medications showed greater improvements in left ventricular size, shape, structure and function than the control group.
Exploratory analyses showed continued improvements in left ventricular ejection fraction and heart size.
- GLP-1 group
- 146 patients
- Control group
- 237 patients
- Study duration
- One year
- Medications
- Semaglutide or tirzepatide
- Heart condition
- Heart failure with reduced ejection fraction